Tag: Ulcerative Colitis
Recommendations Provided for Treatment of Ulcerative Colitis
Infliximab, adalimumab, golimumab, vedolizumab, tofacitinib, ustekinumab recommended over no tx
Colorectal Cancer Risk Still Up in Patients With Ulcerative Colitis
Even after adjustment for tumor stage, patients with ulcerative colitis have higher risk for CRC mortality
Low-FODMAP Diet Relieves Gut Symptoms for More IBD Patients
Adequate relief of gut symptoms reported for more patients following low-FODMAP versus control diet
Risk for Developing Idiopathic Pulmonary Fibrosis Up in IBD
Incidence of IPF significantly higher in patients with Crohn disease than in controls
Vedolizumab Beats Adalimumab for Ulcerative Colitis Remissions
But not for corticosteroid-free clinical remission; also, ustekinumab superior to placebo
Ulcerative Colitis Outcomes Similar for Smokers, Nonsmokers
No significant difference in rates of flares, thiopurine use, hospitalization for persistent smokers, quitters
FDA: Blood Clot, Death Risk Up With Higher Dose of Tofacitinib
Increased risk seen with 10 mg dose of tofacitinib used for treating ulcerative colitis
Infliximab Introduction Has Not Cut IBD-Related Hospitalizations
Introduction of infliximab did not lead to drop in hospitalization, intestinal resection, colectomy
Biomarker Test Predicts Mild, Serious IBD in Newly Diagnosed
Test based on genetic signature of CD8 T cells during active disease
In Men, Low BMI Tied to Later Inflammatory Bowel Disease
Risk lasts through 40 years of adulthood for underweight adolescent men
